All In Biotech

NDA 208799 · Teva Pharm

Airduo Digihaler

Fluticasone Propionate, Salmeterol Xinafoate · Inhalation

Last checked: Nov 20, 2026Latest source record: Nov 16, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Jan 27, 2017

Approved uses

2

Original approval plus efficacy supplements

Registered trials

738

240 Phase 3, 19 recruiting

FAERS reports

2,689

335 serious, 33 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 21, 2025.

Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler (FS MDPI) is indicated for the treatment of asthma in adult and pediatric patients aged 12 years and older. Fluticasone Propionate/Salmeterol MDPI should be used for patients not adequately controlled on a long term asthma control medication such as an inhaled corticosteroid or whose disease warrants initiation of treatment with both an inhaled corticosteroid and long acting beta 2 -adrenergic agonist (LABA). Limitations of Use : Fluticasone Propionate/Salmeterol MDPI is not indicated for the relief of acute bronchospasm. Fluticasone Propionate/Salmeterol Multi-Dose Dry Powder Inhaler (MDPI) is a combination of fluticasone propionate, a corticosteroid, and salmeterol, a long-acting beta 2 -adrenergic agonist (LABA), indicated for treatment of asthma in adult and pediatric patients aged 12 years and older. Fluticasone Propionate/Salmeterol inhalation powder should be used for patients not adequately controlled on a long term asthma control medication such as an inhaled corticosteroid or whose disease warrants initiation of treatment with both an inhaled corticosteroid and long acting beta 2 -adrenergic agonist (LABA). ( 1 ) Limitations of Use : Not indicated for the relief of acute bronchospasm. ( 1 )

Mechanism: This product contains both fluticasone propionate and salmeterol. The mechanisms of action described below for the individual components apply to this combination product. These drugs represent 2 different classes of medications (a synthetic corticosteroid and a LABA) that have different effects on clinical, physiologic, and inflammatory indices. Fluticasone Propionate : Fluticasone propionate is a synthetic trifluorinated corticosteroid with anti-inflammatory activity. Fluticasone propionate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor that is...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

6 products under this application
  • AIRDUO DIGIHALER · FLUTICASONE PROPIONATE 0.113MG/INH; SALMETEROL XINAFOATE EQ 0.014MG BASE/INH · POWDER, INHALATION · Discontinued
  • AIRDUO RESPICLICK · FLUTICASONE PROPIONATE 0.232MG/INH; SALMETEROL XINAFOATE EQ 0.014MG BASE/INH · POWDER, INHALATION · Prescription
  • AIRDUO RESPICLICK · FLUTICASONE PROPIONATE 0.055MG/INH; SALMETEROL XINAFOATE EQ 0.014MG BASE/INH · POWDER, INHALATION · Prescription
  • AIRDUO DIGIHALER · FLUTICASONE PROPIONATE 0.232MG/INH; SALMETEROL XINAFOATE EQ 0.014MG BASE/INH · POWDER, INHALATION · Discontinued
  • AIRDUO DIGIHALER · FLUTICASONE PROPIONATE 0.055MG/INH; SALMETEROL XINAFOATE EQ 0.014MG BASE/INH · POWDER, INHALATION · Discontinued
  • AIRDUO RESPICLICK · FLUTICASONE PROPIONATE 0.113MG/INH; SALMETEROL XINAFOATE EQ 0.014MG BASE/INH · POWDER, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Fluticasone Propionate" as an intervention, any sponsor and status, largest first.

All 738 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • product dose omission issue1,561
  • off label use280
  • product use issue263
  • drug ineffective243
  • dyspnoea198
  • cough98
  • wrong technique in product usage process95
  • accidental underdose85
  • asthma85
  • product use in unapproved indication63
  • dysphonia53
  • headache45

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20081
20092
20101
20121
20141
201711
201854
201950
202050
2021135
2022233
2023281
2024729
2025383
2026757

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Airduo Digihaler (Fluticasone Propion/Salmeterol)

2024 spending

$277K

Beneficiaries

353

506 claims

Per beneficiary

$784

$422.11 per unit

View as table
YearSpending
2020$19,201
2021$268,285
2022$552,626
2023$647,639
2024$276,639

Part D: Airduo Respiclick (Fluticasone Propion/Salmeterol)

2024 spending

$257K

Beneficiaries

346

593 claims

Per beneficiary

$743

$362.27 per unit

View as table
YearSpending
2020$255,537
2021$256,266
2022$272,494
2023$207,498
2024$257,080

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,187 on PubMed

Sponsor: Teva · Also marketed as Airduo Respiclick

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.